Initial Treatment for BAL Galactomannan Positive Patients

First-Line Treatment Options

The Infectious Diseases Society of America recommends voriconazole as the first-line treatment for patients with a positive bronchoalveolar lavage (BAL) galactomannan result indicating probable invasive aspergillosis, with superior efficacy compared to amphotericin B deoxycholate, and significantly better survival rates (71% vs 58% at 12 weeks) and successful outcomes (53% vs 32%) 1, 2, 3
Voriconazole has a recommended dosing regimen, including a loading dose of 6 mg/kg IV every 12 hours for the first 24 hours, and a maintenance dose of 4 mg/kg IV every 12 hours for at least 7 days, with the option to transition to oral therapy at 200 mg twice daily 1, 4
Liposomal amphotericin B (L-AMB) is considered an alternative first-line option for patients who cannot tolerate voriconazole or have contraindications, with a recommended dose of 3 mg/kg/day IV 2, 5

The Infectious Diseases Society of America recommends early initiation of antifungal therapy in seriously ill patients, with parenteral formulation of voriconazole strongly recommended 1, 5
Treatment duration should be at least 6-12 weeks, with continuation of therapy throughout the period of immunosuppression and until lesions have resolved in immunosuppressed patients 1, 4

Serial clinical evaluation of symptoms and signs, regular radiographic imaging with CT, and serial serum galactomannan assays may be useful for monitoring response to treatment 4
Progressive increase in Aspergillus antigen levels over time signifies a poor prognosis 4

Liposomal amphotericin B formulations, echinocandins (caspofungin or micafungin), and itraconazole are options for salvage therapy if initial therapy fails or is not tolerated 1, 2

The Infectious Diseases Society of America recommends oral voriconazole 200 mg twice daily as the standard maintenance dose for outpatient therapy, with a strength of evidence based on superior survival compared to amphotericin B 6, 7

Itraconazole 200 mg twice daily orally is listed as an alternative treatment option, though it is generally considered less preferred than voriconazole, according to the Clinical Infectious Diseases guidelines 6, 7, 8

Therapeutic drug monitoring for voriconazole is strongly recommended due to significant interpatient variability and drug interactions, as suggested by the Journal of Microbiology, Immunology and Infection 8
Patients with CNS involvement, gastrointestinal aspergillosis with bowel wall thickening/necrosis, or disseminated disease require inpatient management with IV therapy and potentially surgical intervention, according to the Clinical Infectious Diseases guidelines 7

Voriconazole has significant CYP450 interactions requiring careful medication review, particularly with immunosuppressants, anticonvulsants, and other azoles, as noted by the Journal of Microbiology, Immunology and Infection 8
Echinocandins are not recommended as primary monotherapy but are effective in salvage therapy, according to the Journal of Microbiology, Immunology and Infection 8